Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Other Non-Current Liabilities came in at $1.9 million in Q1 2026, down 88.5% YoY from $16.2 million in Q1 2025, and down 73.55% on a QoQ basis from $7.0 million in Q4 2025.
Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 88.5% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 88.5% YoY) and the FY2025 annual result came in at $7.0 million, down 60.52% from the prior year.
- Other Non-Current Liabilities fell to $1.9 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $17.8 million in Q4 2024 to a low of $25000.0 in Q4 2022.
- A 5-year average of $7.5 million and a median of $6.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 90485.71% in 2022, down 93.43% in 2022.
- Tracing ZVRA's Other Non-Current Liabilities over 5 years: stood at $25000.0 in 2022, then soared by 64300.0% to $16.1 million in 2023, then climbed by 10.58% to $17.8 million in 2024, then tumbled by 60.52% to $7.0 million in 2025, then sank by 73.55% to $1.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $7.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.17 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 7.03 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 3.32 Mn |
| Mar 31, 2025 | 16.17 Mn |
| Dec 31, 2024 | 17.80 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 6.64 Mn |
| Mar 31, 2024 | 8.54 Mn |
| Dec 31, 2023 | 16.10 Mn |
| Sep 30, 2023 | 5.95 Mn |
| Jun 30, 2023 | 9.62 Mn |
| Mar 31, 2023 | 11.74 Mn |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 26,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 12.68 Mn |
| Dec 31, 2021 | 31,000.00 |
| Sep 30, 2021 | 396,000.00 |